Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors.
Early breast cancer
Rheumatoid arthritis
Survival
Tumor necrosis factor inhibitors
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
received:
13
06
2024
accepted:
13
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) for autoimmune disease in patients with recently diagnosed cancer. We assessed the survival of patients with rheumatoid arthritis (RA) and newly diagnosed early breast cancer (BC) treated with TNFi in the first two years after BC diagnosis. We identified patients in two datasets: (1) Optum's de-identified Clinformatics In the first year after BC, 165/970 (17.0%) and 201/1246 (16.1%) patients received TNFi in CDM and SEER/TCR-Medicare respectively. In the 1 year landmark, no significant differences in OS were observed between patients treated with TNFi and patients treated with csDMARDs only in CDM (hazard ratio [HR] = 0.77, 95% confidence interval [CI] 0.42-1.40) or SEER/TCR-Medicare (HR = 0.84, 95% CI 0.54-1.31). BCSS (SEER/TCR-Medicare) was better in patients receiving TNFi than in those receiving csDMARDs only (HR = 0.28, 95% CI 0.08-0.98). In CDM, glucocorticoid therapy had worse OS than those without glucocorticoids (HR = 2.18, 95% CI 1.13-4.18). This was also observed in SEER/TCR-Medicare (not statistically significant). Similar results were observed for the 2 year landmark. TNFi treatment during the first two years after early BC was not associated with worse survival.
Sections du résumé
BACKGROUND
BACKGROUND
There have been concerns about the use of tumor necrosis factor inhibitors (TNFi) for autoimmune disease in patients with recently diagnosed cancer. We assessed the survival of patients with rheumatoid arthritis (RA) and newly diagnosed early breast cancer (BC) treated with TNFi in the first two years after BC diagnosis.
METHODS
METHODS
We identified patients in two datasets: (1) Optum's de-identified Clinformatics
RESULTS
RESULTS
In the first year after BC, 165/970 (17.0%) and 201/1246 (16.1%) patients received TNFi in CDM and SEER/TCR-Medicare respectively. In the 1 year landmark, no significant differences in OS were observed between patients treated with TNFi and patients treated with csDMARDs only in CDM (hazard ratio [HR] = 0.77, 95% confidence interval [CI] 0.42-1.40) or SEER/TCR-Medicare (HR = 0.84, 95% CI 0.54-1.31). BCSS (SEER/TCR-Medicare) was better in patients receiving TNFi than in those receiving csDMARDs only (HR = 0.28, 95% CI 0.08-0.98). In CDM, glucocorticoid therapy had worse OS than those without glucocorticoids (HR = 2.18, 95% CI 1.13-4.18). This was also observed in SEER/TCR-Medicare (not statistically significant). Similar results were observed for the 2 year landmark.
CONCLUSIONS
CONCLUSIONS
TNFi treatment during the first two years after early BC was not associated with worse survival.
Identifiants
pubmed: 39117793
doi: 10.1007/s12282-024-01618-x
pii: 10.1007/s12282-024-01618-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAMS NIH HHS
ID : R01AR078484
Pays : United States
Organisme : NIH/National Cancer Institute through MD Anderson's Cancer Center Support Grant
ID : P30CA016672
Organisme : Susan G. Komen
ID : SAC150061
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.
Références
Singh N, Grivas P, Makris UE, Suarez-Almazor ME, O’Hare AM, Barton JL. Use of disease-modifying antirheumatic drugs in rheumatoid arthritis: supporting shared decision-making between patients with cancer and clinicians. ACR Open Rheumatol. 2023;5(6):305–7.
doi: 10.1002/acr2.11552
pubmed: 37166652
pmcid: 10267802
Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol. 2021;17(4):213–23.
doi: 10.1038/s41584-021-00584-4
pubmed: 33686279
pmcid: 8366509
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Segui B. The TNF paradox in cancer progression and immunotherapy. Front Immunol. 2019;10:1818.
doi: 10.3389/fimmu.2019.01818
pubmed: 31417576
pmcid: 6685295
Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B, et al. Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. Arthritis Care Res (Hoboken). 2023;75(2):260–71.
doi: 10.1002/acr.24784
pubmed: 34549898
Phan H, Weideman RA, Cipher DJ, Feagins LA. Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy. Intest Res. 2020;18(3):282–8.
doi: 10.5217/ir.2019.09140
pubmed: 32252501
pmcid: 7385568
Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Leung CH, et al. Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clin Rheumatol. 2020;39(10):2943–50.
doi: 10.1007/s10067-020-05318-7
pubmed: 32803571
pmcid: 10556973
Dreyer L, Cordtz RL, Hansen IMJ, Kristensen LE, Hetland ML, Mellemkjaer L. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis. 2018;77(4):510–4.
doi: 10.1136/annrheumdis-2017-212086
pubmed: 29217620
Raaschou P, Söderling J, Turesson C, Askling J. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med. 2018;169(5):291–9.
doi: 10.7326/M17-2812
pubmed: 30105374
Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5.
doi: 10.1186/ar2904
pubmed: 20064207
pmcid: 2875631
Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010;62(6):755–63.
doi: 10.1002/acr.20129
pubmed: 20535785
Phillips C, Zeringue AL, McDonald JR, Eisen SA, Ranganathan P. Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis. PLoS One. 2015;10(11): e0143286.
doi: 10.1371/journal.pone.0143286
pubmed: 26599370
pmcid: 4658068
Silva-Fernández L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DPM, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology. 2016;55(11):2033–9.
doi: 10.1093/rheumatology/kew314
pubmed: 27550304
pmcid: 5088627
National Cancer Institute. Division of Cancer Control and Population Sciences. SEER-Medicare Linked Data Resource: National Cancer Institute. 2022. https://healthcaredelivery.cancer.gov/seermedicare/ . Accessed Dec 2022.
Enewold L, Parsons H, Zhao L, Bott D, Rivera DR, Barrett MJ, et al. Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020;2020(55):3–13.
pubmed: 32412076
pmcid: 7225666
Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31(8):732–48.
doi: 10.1097/00005650-199308000-00006
pubmed: 8336512
Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363: k3532.
doi: 10.1136/bmj.k3532
pubmed: 30429167
pmcid: 6234471
Table describing changes in codes for NCI comorbidity index. 2023. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity-table.html . Accessed Nov 2023.
Pundole X, Suarez-Almazor ME. Cancer and rheumatoid arthritis. Rheum Dis Clin North Am. 2020;46(3):445–62.
doi: 10.1016/j.rdc.2020.05.003
pubmed: 32631599
Raaschou P, Frisell T, Askling J. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74(12):2137–43.
doi: 10.1136/annrheumdis-2014-205745
pubmed: 25107559
Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276–84.
doi: 10.1016/S2468-1253(19)30362-0
pubmed: 31836320
de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361(7):653–63.
doi: 10.1056/NEJMoa0904832
pubmed: 19675329
Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1–18.
doi: 10.1007/s13402-019-00489-1
pubmed: 31900901
Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(19):6528–34.
doi: 10.1158/1078-0432.CCR-04-0730
pubmed: 15475440
Khadka S, Druffner SR, Duncan BC, Busada JT. Glucocorticoid regulation of cancer development and progression. Front Endocrinol (Lausanne). 2023;14:1161768.
doi: 10.3389/fendo.2023.1161768
pubmed: 37143725
Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol. 2006;7(5):425–30.
doi: 10.1016/S1470-2045(06)70694-5
pubmed: 16648047
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399(10336):1695–707.
doi: 10.1016/S0140-6736(22)00367-1
pubmed: 35405085
Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415–21.
doi: 10.1136/annrheumdis-2013-204021
pubmed: 24291654